1. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas. Diabetes research and clinical practice. 2019;157:107843. [
DOI:10.1016/j.diabres.2019.107843]
2. Haghdoost AA, Rezazadeh Kermani M, Sadghirad B, Baradaran HR. Prevalence of type 2 diabetes in the Islamic Republic of Iran: systematic review and meta-analysis. EMHJ-Eastern Mediterranean Health Journal, 2009;15(3):591-599. [
DOI:10.26719/2009.15.3.591]
3. Javanbakht M, Mashayekhi A, Baradaran HR, Haghdoost A, Afshin A. Projection of diabetes population size and associated economic burden through 2030 in Iran: evidence from micro-simulation Markov model and Bayesian meta-analysis. PloS one. 2015;10(7):e0132505. [
DOI:10.1371/journal.pone.0132505]
4. Care D. 6. Glycemic targets: standards of medical care in diabetes-2019. Diabetes Care. 2019;42(Supplement 1):S61-70. [
DOI:10.2337/dc19-S006]
5. Zimmerman RS. Diabetes mellitus: management of microvascular and macrovascular complications. J Cleveland Clinic: Centers for Continuing Education. 2016.
6. Khavjou OA, Saydah SH, Zhang P, Poehler DC, Neuwahl SJ, Leib AR, et al. Estimating State-Level Health Burden of Diabetes: Diabetes-Attributable Fractions for Diabetes Complications. American journal of preventive medicine. 2019;56(2):232-40. [
DOI:10.1016/j.amepre.2018.09.023]
7. Rasolabadi M, Khaledi S, Ardalan M, Kalhor MM, Penjvini S, Gharib A. Diabetes research in Iran: a scientometric analysis of publications output. Acta Informatica Medica. 2015 ;23(3):160-164. [
DOI:10.5455/aim.2015.23.160-164]
8. Mathew TK, Tadi P. Blood Glucose Monitoring. StatPearls [Internet]. 2020.
9. Harrabi I, Al Harbi F, Al Ghamdi S. Predictors of glycemic control among patients with type 2 diabetes in Najran Armed Forces Hospital: a pilot study. Journal of Diabetes Mellitus. 2014;4(02):141. [
DOI:10.4236/jdm.2014.42021]
10. Camara A, Baldé NM, Sobngwi-Tambekou J, Kengne AP, Diallo MM, Tchatchoua AP, et al. Poor glycemic control in type 2 diabetes in the South of the Sahara: the issue of limited access to an HbA1c test. Diabetes research and clinical practice. 2015;108(1):187-92. [
DOI:10.1016/j.diabres.2014.08.025]
11. Gopinath B, Prasad SM, Jayarama N, Prabhakara K. Study of factors associated with poor glycemic control in Type-2 Diabetic patients. Global journal of Medicine and public health. 2013;2(2):1-5.
12. Abougalambou S, Suleiman A, Abougalambou A. Glycaeted haemoglobin control among type 2 diabetes patients attending a teaching hospital in Malaysia. Saudi Journal of Medical Pharmaceutical Science. 2015;15:93-102.
13. Pablo CR, Mohammadnezhad M, Wilson D, Khan S. Socio-demographic Determinants of Poor Glycaemic Control among Type 2 Diabetes Mellitus (T2DM) Patients Attending Clinics at the Three Selected Health Facilities in Suva, Fiji in 2011-2016. Journal of Diabetic Complications & Medicine. 2018;3(1).
14. Adeniyi OV, Yogeswaran P, Longo-Mbenza B, Ter Goon D, Ajayi AI. Cross-sectional study of patients with type 2 diabetes in OR Tambo district, South Africa. BMJ open. 2016;6(7):e010875. [
DOI:10.1136/bmjopen-2015-010875]
15. Saghir SA, Alhariri AE, Alkubati SA, Almiamn AA, Aladaileh SH, Alyousefi NA. Factors associated with poor glycemic control among type-2 diabetes mellitus patients in Yemen. Tropical Journal of Pharmaceutical Research. 2019;18(7).
16. de Pablos‐Velasco P, Parhofer KG, Bradley C, Eschwege E, Gönder-Frederick L, Maheux P, et al. Current level of glycaemic control and its associated factors in patients with type 2 diabetes across Europe: data from the PANORAMA study. Clinical endocrinology. 2014;80(1):47-56. [
DOI:10.1111/cen.12119]
17. Kellow NJ, Savige GS, Khalil H. Predictors of poor glycaemic control during the initial five years post‐diagnosis in rural adults with type 2 diabetes. Australian Journal of Rural Health. 2011;19(5):267-74. [
DOI:10.1111/j.1440-1584.2011.01222.x]
18. Jyun-You L, Chia-Fen M, Chao-Yu H. Medical appointment no-shows associated with poor glycaemic control among Taiwanese aborigines. Australian Journal of Rural Health. 2012;20(6):312-7. [
DOI:10.1111/j.1440-1584.2012.01310.x]
19. Hasan C, Parial R, Islam M, Ahmad MNU, Kasru A. Association of HbA1c, Creatinine and Lipid Profile in Patients with Diabetic Foot Ulcer. Middle-East Journal of Scientific Research. 2013 01/01;16:1508-11.
20. Christman AL, Selvin E, Margolis DJ, Lazarus GS, Garza LA. Hemoglobin A1c predicts healing rate in diabetic wounds. Journal of Investigative Dermatology. 2011;131(10):2121-7. [
DOI:10.1038/jid.2011.176]
21. Zubair M, Malik A, Ahmad J. Glycosylated hemoglobin in diabetic foot and its correlation with clinical variables in a north Indian tertiary care hospital. Journal of Diabetes and Metabolism. 2015;6(7). [
DOI:10.4172/2155-6156.1000571]
22. Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. Nature Reviews Endocrinology. 2009;5(3):150-9. [
DOI:10.1038/ncpendmet1066]
23. Hirano T. Pathophysiology of diabetic dyslipidemia. Journal of atherosclerosis and thrombosis. 2018;25(9):771-82. [
DOI:10.5551/jat.RV17023]
24. Dixit AK, Dey R, Suresh A, Chaudhuri S, Panda AK, Mitra A, et al. The prevalence of dyslipidemia in patients with diabetes mellitus of ayurveda Hospital. Journal of Diabetes & Metabolic Disorders. 2014;13(1):1-6. [
DOI:10.1186/2251-6581-13-58]
25. Esteghamati A, Larijani B, Aghajani MH, Ghaemi F, Kermanchi J, Shahrami A, et al. Diabetes in Iran: prospective analysis from first nationwide diabetes report of National Program for Prevention and Control of Diabetes (NPPCD-2016). Scientific reports. 2017;7(1):1-0. [
DOI:10.1038/s41598-017-13379-z]
26. Ozder A. Lipid profile abnormalities seen in T2DM patients in primary healthcare in Turkey: a cross-sectional study. Lipids in health and disease. 2014;13(1):1-6. [
DOI:10.1186/1476-511X-13-183]
27. Dabla PK. Renal function in diabetic nephropathy. World journal of diabetes. 2010;1(2):48-56. [
DOI:10.4239/wjd.v1.i2.48]
28. Perkovic V, Jardine M, Vijapurkar U, Meininger G. Renal effects of canagliflozin in type 2 diabetes mellitus. Current medical research and opinion. 2015;31(12):2219-31. [
DOI:10.1185/03007995.2015.1092128]
29. Al Nozha OM. Diabetes care and control: the effect of frequent visits to diabetes care center. Annals of Saudi medicine. 2014;34(3):229-34. [
DOI:10.5144/0256-4947.2014.229]